Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.

Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.

Leave a Comment / Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. / By

In breast cancer patients undergoing neoadjuvant chemotherapy before surgery, there is an unmet need for non-invasive biomarkers predictive of response. Analysis of DNA circulating tumor (ctDNA) in particular has been the object of several reports, but some of them have studied the application of targeted sequencing marked in (tTDS) for clinical practice and performance compared …

Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Read More »

Genetic diversity, population structure, and relationships of apricot (Prunus) based on restriction site-associated DNA sequencing.

Genetic diversity, population structure, and relationships of apricot (Prunus) based on restriction site-associated DNA sequencing.

Leave a Comment / Genetic diversity, population structure, and relationships of apricot (Prunus) based on restriction site-associated DNA sequencing. / By

Single-nucleotide polymorphisms (SNPs) are the most abundant form of genomic polymorphism and is widely used in population genetics research. Here, the high-throughput sequencing is used to test the genome-level diversity, population structure, and relationships apricots, which are important for the conservation of germplasm and molecular breeding. Restriction-site associated DNA sequencing (RAD-seq) adopted to sequence 168 …

Genetic diversity, population structure, and relationships of apricot (Prunus) based on restriction site-associated DNA sequencing. Read More »

Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer.

Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer.

Leave a Comment / Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer. / By

Neoantigens evolutionary dynamics related tumors carry information on drug sensitivity and resistance to immune checkpoint blockade (ICB). However, the spectrum of somatic mutations are very heterogeneous between patients, making it difficult to track neoantigens by circulating tumor DNA (ctDNA) sequencing using a “one size fits all” commercial gene panel. Thus, individually adjustable panel (ICPs) that …

Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer. Read More »

Scroll to Top